Palisade bio transforms gi-focused pipeline through exclusive worldwide licensing agreement with giiant pharma, inc. for multiple oral drug candidates targeting inflammatory bowel disease

– lead program, gt-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of i nd-enabling studies with ind filing expected by q3 2024
PALI Ratings Summary
PALI Quant Ranking